Study design (if review, criteria of inclusion for studies)
randomized, controlled trial
Participants
20 adult patients with cystic fibrosis who were experiencing acute pulmonary exacerbations
Interventions
oral ciprofloxacin and intravenous tobramycin plus azlocillin.
Outcome measures
Efficacy of the two treatments was compared based upon changes in clinical status, pulmonary function tests, white blood cell counts, and quantitative bacteriology of sputum
Main results
No statistically significant differences were detected in these parameters of response between the two treatment groups (p greater than 0.05).
Authors' conclusions
Ciprofloxacin appears to be therapeutically equivalent to intravenous antibiotics in the treatment of adult patients with cystic fibrosis who are experiencing pulmonary exacerbations associated with susceptible bacteria.